Arcutis Biotherapeutics, Inc. (ARQT) stock
ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30415% above fair value
$27.17−0.44 (-1.59%)
Close on Nov 19, 2026Market cap $3.42BP/E 123.5Yield –
Arcutis Biotherapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Arcutis Biotherapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $39.15M. For fiscal 2025 it was -$6.31M. The highest annual figure on record is -$6.31M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.31M | – |
| FY2024 | Dec 31, 2024 | -$112.30M | – |
| FY2023 | Dec 31, 2023 | -$247.49M | – |
| FY2022 | Dec 31, 2022 | -$258.05M | – |
| FY2021 | Dec 31, 2021 | -$175.62M | – |
| FY2020 | Dec 31, 2020 | -$113.35M | – |
| FY2019 | Dec 31, 2019 | -$43.13M | – |
| FY2018 | Dec 31, 2018 | -$14.09M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.48M | +4973.6% |
| Q1 FY2026 | Mar 31, 2026 | $2.24M | – |
| Q4 FY2025 | Dec 31, 2025 | $26.19M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.75M | – |
| Q2 FY2025 | Jun 30, 2025 | $246.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$30.99M | – |
| Q4 FY2024 | Dec 31, 2024 | -$748.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.83M | – |
| Q2 FY2024 | Jun 30, 2024 | -$45.12M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.60M | – |
| Q4 FY2023 | Dec 31, 2023 | -$56.25M | – |
| Q3 FY2023 | Sep 30, 2023 | -$44.05M | – |
| Q2 FY2023 | Jun 30, 2023 | -$66.76M | – |
| Q1 FY2023 | Mar 31, 2023 | -$80.43M | – |
| Q4 FY2022 | Dec 31, 2022 | -$71.19M | – |
| Q3 FY2022 | Sep 30, 2022 | -$67.70M | – |
| Q2 FY2022 | Jun 30, 2022 | -$62.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$57.10M | – |
| Q4 FY2021 | Dec 31, 2021 | -$51.97M | – |
| Q3 FY2021 | Sep 30, 2021 | -$41.02M | – |
| Q2 FY2021 | Jun 30, 2021 | -$35.87M | – |
| Q1 FY2021 | Mar 31, 2021 | -$46.76M | – |
| Q4 FY2020 | Dec 31, 2020 | -$32.72M | – |
| Q3 FY2020 | Sep 30, 2020 | -$33.80M | – |
| Q2 FY2020 | Jun 30, 2020 | -$25.78M | – |
| Q1 FY2020 | Mar 31, 2020 | -$21.05M | – |
| Q4 FY2019 | Dec 31, 2019 | -$16.86M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.73M | – |
| Q2 FY2019 | Jun 30, 2019 | -$8.29M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.26M | – |
See a number that looks wrong?